Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

Effect of prior therapy on BRAF V600E-mutant metastatic colorectal cancer

11 Jun 2021Oncology

Coco Chong

Share

This content is sponsored. It is intended for healthcare professionals only.

An exploratory post-hoc analysis of the BEACON CRC study investigated the overall survival (OS) of encorafenib + cetuximab (doublet) and FOLFIRI (control) according to prior therapies (bevacizumab, oxaliplatin, FOLFOXIRI and anticancer therapy ) in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Effect-of-prior-therapy-on-BRAF-V600E-mutant-metastatic-colorectal-cancer

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026